3,516
Views
4
CrossRef citations to date
0
Altmetric
Health Technology

Informing a cost-effectiveness threshold for Saudi Arabia

ORCID Icon, ORCID Icon, , ORCID Icon, , , , ORCID Icon, ORCID Icon, , & show all
Pages 128-138 | Received 01 Sep 2022, Accepted 07 Dec 2022, Published online: 18 Jan 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mac Ardy Junio Gloria, Montarat Thavorncharoensap, Usa Chaikledkaew, Sitaporn Youngkong, Ammarin Thakkinstian, Nathorn Chaiyakunapruk, Jessica Ochalek & Anthony J. Culyer. (2024) Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds. Expert Review of Pharmacoeconomics & Outcomes Research 24:2, pages 203-215.
Read now

Articles from other publishers (3)

Areej S. Albahdal, Amjad M. Alotaibi, Miteb A. Alanazi, Norah Abanmy, Monira Alwhaibi & Yazed AlRuthia. (2024) Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study. Cost Effectiveness and Resource Allocation 22:1.
Crossref
Yazed AlRuthia, Almaha H. Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A. Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh & Majed Ali Almasaoud. (2023) Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia. Cost Effectiveness and Resource Allocation 21:1.
Crossref
Nahla Azzam, Majid Almadi, Mansour Altuwaijiri, Othman Alharbi, Abdulrahman Aljebreen, Suliman Alshankiti & Yazed Alruthia. (2023) Cost-Consequence Analysis of Colon Cancer Screening among Patients with Long-Standing Ulcerative Colitis: 11 Years’ Experience of Saudi Population. Saudi Pharmaceutical Journal 31:12, pages 101883.
Crossref